GET DAILY SIGNALSVascular Group's Tickers $ANGO, $AORT, $LMAT, $AKBA, and $AVGR Surge +27.39% in Weekly Performance
The Vascular sector has been making waves in the financial markets, with a remarkable surge of 27.39% in performance over the past week. This impressive performance has piqued the interest of investors and analysts alike. In this article, we will delve into this exciting theme and explore the group of tickers driving this growth. From positive momentum indicators to notable price movements and volume surges, we'll dissect the factors contributing to this sector's success.
The Vascular Tickers
The Vascular theme comprises several key tickers that have contributed to this exceptional performance. These tickers include:
-
ANGO (AngioDynamics): A player in the vascular sector, AngioDynamics has been part of the recent upward trend.
-
AORT (AORTA): AORTA, another significant player, has also been a contributor to the theme's positive momentum.
-
LMAT (LeMaitre Vascular): LeMaitre Vascular is a prominent company within the vascular sector, with a market capitalization that places it among the top players.
-
AKBA (Akebia Therapeutics): Akebia Therapeutics has been in the spotlight recently, although it experienced a weekly decline during the reporting period.
-
AVGR (Avinger): Avinger, while showing volatility, has had a notable presence within the vascular group.
Positive Outlook and Momentum
The Vascular theme has garnered a positive outlook, supported by the Momentum Indicator. Tickeron, a respected financial analysis tool, predicts a further increase of more than 4.00% within the next month for this group, with a likelihood of 70%. This prediction is based on a robust historical ratio of advancing to declining volumes, which stood at 4.06 to 1 during the last month. In fact, five of the stocks within this ticker group exhibit a similar positive trend based on the Advances indicator, with an average likelihood of 78%.
Market Capitalization
The average market capitalization across the Vascular Theme is $486 million. This indicates that this theme encompasses a mix of both mid-sized and smaller companies. Notably, LMAT stands out with the highest valuation in this group, boasting a market cap of $1.3 billion. On the other end of the spectrum, AVGR holds the position of the lowest valued company within the group, with a market cap of $8.6 million.
High and Low Price Movements
The recent performance of stocks within the vascular theme has been marked by significant price movements. On average, these stocks experienced a weekly price growth of 27.39%, showcasing the impressive short-term gains. However, the average monthly price growth was -1.72%, indicating that the theme has experienced some volatility over a slightly longer timeframe. The average quarterly price growth stands at 14.14%, indicating that these stocks have delivered strong gains over a three-month period. Notably, AVGR experienced the highest price growth at 197.84%, while ANGO experienced the biggest fall at -4.44%.
Volume Surges
The volume surges within the Vascular theme have been nothing short of extraordinary. On average, these stocks witnessed a weekly volume growth of 998.52%, a substantial increase that reflects heightened market interest. Over a monthly period, the average volume growth was 1401.37%, and for a quarter, it stood at 1655.93%. These remarkable figures suggest that investors have been actively trading these stocks, further fueling their upward momentum.
Notable volume events include AngioDynamics (ANGO) experiencing a record-breaking daily growth of 1,329% of the 65-Day Volume Moving Average on September 16, 2023, and consecutive volume increases over multiple days.
Fundamental Analysis Ratings
The fundamental analysis ratings provide valuable insights into the health and potential of these vascular theme stocks. These ratings cover various aspects, with lower values generally indicating better performance. Here's a summary of the ratings:
- Valuation Rating: 55
- P/E Growth Rating: 83
- Price Growth Rating: 53
- SMR Rating: 91
- Profit Risk Rating: 84
- Seasonality Score: -65 (-100 ... +100)
These ratings offer a comprehensive view of the fundamental health and growth potential of the stocks within this theme.
Summary
The Vascular sector has been a standout performer in recent times, with impressive gains, notable volume surges, and positive outlooks for many key tickers. While there are individual fluctuations and challenges, the overall outlook remains optimistic. Investors and analysts will be closely monitoring these stocks to see if they can sustain this upward momentum and continue delivering value to shareholders in the coming months.
Contributor
ANGO in downward trend: 10-day moving average crossed below 50-day moving average on October 05, 2026
The 10-day moving average for ANGO crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 57 cases where ANGO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANGO as a result. In 67 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
ANGO moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for ANGO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANGO's RSI Indicator exited the oversold zone, 24 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for ANGO just turned positive on October 23, 2026. Looking at past instances where ANGO's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
Following a +4.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANGO advanced for three days, in 197 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ANGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.838) is normal, around the industry mean (4.955). P/E Ratio (-13.330) is within average values for comparable stocks, (40.806). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.005) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. ANGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical devices used by radiologists, vascular surgeons and other physicians
Industry PharmaceuticalsOther
Advertisement